T6251

PF-04691502 is a potent and selective inhibitor of PI3K and mTOR kinases with antitumor activity.

IHMT-MST1-58 is a STE20-like protein 1 kinase (MST1) inhibitor (IC50:23 nM) with high efficiency, selectivity and oral activity. IHMT-MST1-58 can be used to study type 1 or type 2 diabetes.

Antitumor agent-75 is a novel and potent antitumor agent with cytotoxic effects on both cancer and normal human cell lines. In combination with antitumor agent-74, Antitumor agent-75 exhibits a highly selective cytotoxic effect (IC50: 2.8 μM) against human lung adenocarcinoma [cell line A549]. Antitumor agent-75 is applicable in cancer research.

AZ3391 is a quinoxaline derivative that is a potent inhibitor of PARP. AZ3391 has potential for the study of diseases and conditions occurring in central nervous system tissues (e.g., brain and spinal cord).

MAX-40279 is a potent, dual FLT3 kinase and FGFR kinase inhibitor. MAX-40279 has potential for acute myeloid leukemia (AML) studies.

HDAC-IN-46 (compound 12c) is a potent inhibitor of HDAC, targeting HDAC1 (IC50: 0.21 μM) and HDAC6 (IC50: 0.021 μM). It upregulates p-p38, downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells, blocks the cell cycle in the G2 phase, and induces apoptosis, making it useful for triple negative breast cancer (TNBC) studies.

SIRT2-IN-9 is a selective SRIT2 inhibitor with an IC50 value of 1.3 μM.SIRT2-IN-9 inhibits the proliferation of MCF-7 breast cancer cells.SIRT2-IN-9 can be used for cancer research.

SV5 is a potent anti-Alzheimer agent that significantly protects SHSY-5Y cells from Aβ1-42-induced death. It is highly stable, has optimal pharmacological properties in human plasma, and demonstrates appropriate antioxidant and good neuroprotective activity.

S1P receptor agonist 2 (compound 1) is a selective agonist of the S1P5 receptor, exhibiting higher selectivity than for S1P1 and/or S1P3 receptors. It is useful in the endogenous SIP signaling system and for mitigating or preventing central nervous system (CNS) diseases, including neurodegenerative diseases.

GRK6-IN-1 (compound 18) is a potent inhibitor of G protein-coupled receptor kinase 6 (GRK6) with an IC50 of 120 nM, and has potential for study in multiple myeloma.

SW02 is a potent ATPase activator of Hsp70 (EC50: 150 μM). SW02 is able to accumulate total tau and phosphorylated tau (pTau).